Achillion Pharmaceuticals, Inc. Reports Interim Results on ACH-3102

NEW HAVEN, Conn., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has completed enrollment in a pilot Phase 2a trial evaluating ACH-3102, a second-generation pan-genotypic NS5A inhibitor, in combination with ribavirin for the treatment of patients with chronic genotype 1b (GT 1b) hepatitis C virus (HCV) infection. The initial cohort enrolled eight patients with GT 1b HCV, IL28b genotype CC, that are receiving twelve weeks of ACH-3102 once daily in combination with ribavirin.